BDSX Biodesix

Biodesix to Participate in Three Investor Conferences in November

Biodesix to Participate in Three Investor Conferences in November

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Craig-Hallum 15th Annual Alpha Select Conference

1x1 Meetings

Date: Tuesday, November 19, 2024

Location: New York, NY

Wolfe Research Healthcare Conference 2024

1x1 Meetings

Date: Wednesday, November 20, 2024

Location: New York, NY

Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum

Presentation and 1x1 Meetings

Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET

Location: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit .

Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
29/10/2024

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Third Quarter 2025 Results and Highlights

Biodesix Announces Third Quarter 2025 Results and Highlights Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. “We delivered a strong third quarter with revenue growing 20% to $...

10h / 54m 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Share its R&D Roadmap during its Corporate Day Presentatio...

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific LOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence at the 2025 AMP Annual Meeting, November 12-15, in Boston, MA. BIODESIX WORKSHOP: On November 12, at 4:00 ET, Dr. ...

October 30, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement...

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing  LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensi...

October 22, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Report Third Quarter 2025 Financial Results on November 3,...

Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025 LOUISVILLE, Colo., Oct. 20, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2025 after the close of trading on Monday, November 3. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate...

October 20, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces Presentations and Events at the CHEST 2025 Annual M...

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois. Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation. Title: Prese...

October 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch